NL7117256A - - Google Patents

Info

Publication number
NL7117256A
NL7117256A NL7117256A NL7117256A NL7117256A NL 7117256 A NL7117256 A NL 7117256A NL 7117256 A NL7117256 A NL 7117256A NL 7117256 A NL7117256 A NL 7117256A NL 7117256 A NL7117256 A NL 7117256A
Authority
NL
Netherlands
Application number
NL7117256A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7117256A publication Critical patent/NL7117256A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
NL7117256A 1970-12-17 1971-12-16 NL7117256A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB6006470A GB1380246A (en) 1970-12-17 1970-12-17 3alpha-hydroxy-androstanes and esters thereof
GB6007070 1970-12-17

Publications (1)

Publication Number Publication Date
NL7117256A true NL7117256A (cg-RX-API-DMAC7.html) 1972-06-20

Family

ID=26267810

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7117256A NL7117256A (cg-RX-API-DMAC7.html) 1970-12-17 1971-12-16

Country Status (7)

Country Link
AU (1) AU473307B2 (cg-RX-API-DMAC7.html)
BE (1) BE776791A (cg-RX-API-DMAC7.html)
DE (1) DE2162595A1 (cg-RX-API-DMAC7.html)
FR (1) FR2118123B1 (cg-RX-API-DMAC7.html)
GB (1) GB1380246A (cg-RX-API-DMAC7.html)
IL (1) IL38378A (cg-RX-API-DMAC7.html)
NL (1) NL7117256A (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1434919A (en) * 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
EP3728285B1 (en) * 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
CA3086299A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物

Also Published As

Publication number Publication date
AU473307B2 (en) 1976-06-17
IL38378A (en) 1979-01-31
FR2118123B1 (cg-RX-API-DMAC7.html) 1975-11-28
AU3695871A (en) 1973-06-21
FR2118123A1 (cg-RX-API-DMAC7.html) 1972-07-28
GB1380246A (en) 1975-01-08
DE2162595A1 (de) 1972-07-06
IL38378A0 (en) 1972-02-29
BE776791A (fr) 1972-06-16

Similar Documents

Publication Publication Date Title
CH1712871A4 (cg-RX-API-DMAC7.html)
FR2118123A1 (cg-RX-API-DMAC7.html)
FR2076103B1 (cg-RX-API-DMAC7.html)
DK130200C (cg-RX-API-DMAC7.html)
FR2076125A1 (cg-RX-API-DMAC7.html)
FR2081940B1 (cg-RX-API-DMAC7.html)
DK130534C (cg-RX-API-DMAC7.html)
FR2076088B3 (cg-RX-API-DMAC7.html)
FR2084370A5 (cg-RX-API-DMAC7.html)
FR2081738B3 (cg-RX-API-DMAC7.html)
FR2074556A1 (cg-RX-API-DMAC7.html)
FR2077695A1 (cg-RX-API-DMAC7.html)
FR2084897A5 (cg-RX-API-DMAC7.html)
DE2031329C3 (cg-RX-API-DMAC7.html)
FR2076618A5 (cg-RX-API-DMAC7.html)
CS166353B1 (cg-RX-API-DMAC7.html)
DE2152647B2 (cg-RX-API-DMAC7.html)
DE2112846C3 (cg-RX-API-DMAC7.html)
FR2059848A5 (cg-RX-API-DMAC7.html)
FR2058979A5 (cg-RX-API-DMAC7.html)
DE2057398C3 (cg-RX-API-DMAC7.html)
DK134693C (cg-RX-API-DMAC7.html)
CS151948B1 (cg-RX-API-DMAC7.html)
RO56966A2 (cg-RX-API-DMAC7.html)
CS151231B1 (cg-RX-API-DMAC7.html)